Brief: Paratek Pharmaceuticals To Be Acquired By Gurnet Point Capital And Novo Holdings
06/06/2023 15:22
June 6 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS TO BE ACQUIRED BY GURNET POINT
CAPITAL
AND NOVO HOLDINGS
* PARATEK PHARMACEUTICALS INC - TOTAL TRANSACTION
CONSIDERATION OF
UP TO APPROXIMATELY $462 MILLION
* PARATEK PHARMACEUTICALS INC - DEBT FINANCING OF $175
MILLION FOR
TRANSACTION WILL BE PROVIDED BY FUNDS MANAGED BY OAKTREE CAPITAL
MANAGEMENT, L.P.
* PARATEK PHARMACEUTICALS - PROPOSED DEAL FOR $2.15/SHARE IN
CASH,
PLUS CVR OF $0.85/SHARE PAYABLE UPON ACHIEVEMENT OF $320 MILLION
IN U.S. NUZYRA NET SALES
* PARATEK PHARMACEUTICALS INC - FOLLOWING COMPLETION,
PARATEK WILL
BECOME A PRIVATE COMPANY
Source text for Eikon: ID:nGNX1l5Mmv
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million